tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ALGS Stock Latest News

Aligos Therapeutics appoints James Hassard as EVP, CCO
The FlyAligos Therapeutics appoints James Hassard as EVP, CCO
2d ago
ALGS
Aligos Therapeutics initiated with a Buy at UBS
PremiumThe Fly
Aligos Therapeutics initiated with a Buy at UBS
8d ago
IVA
KOD
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
PremiumThe Fly
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
1M ago
ALGS
Aligos Therapeutics: Promising Developments in Liver Disease Programs and Strategic Pipeline Drive Buy Rating
PremiumRatings
Aligos Therapeutics: Promising Developments in Liver Disease Programs and Strategic Pipeline Drive Buy Rating
1M ago
ALGS
Aligos Therapeutics presents pevifoscorvir, ALG-055009 data at HEP-DART
PremiumThe Fly
Aligos Therapeutics presents pevifoscorvir, ALG-055009 data at HEP-DART
1M ago
ALGS
Aligos Therapeutics: Strong Buy Rating Backed by Promising Liver Disease Treatments and Strategic Positioning
PremiumRatingsAligos Therapeutics: Strong Buy Rating Backed by Promising Liver Disease Treatments and Strategic Positioning
2M ago
ALGS
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
Premium
The Fly
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
2M ago
ALGS
Aligos Therapeutics presents data from eight presentations at AASLD
Premium
The Fly
Aligos Therapeutics presents data from eight presentations at AASLD
2M ago
ALGS
Aligos Therapeutics: Strategic Execution and Promising Pipeline Drive Buy Rating
PremiumRatings
Aligos Therapeutics: Strategic Execution and Promising Pipeline Drive Buy Rating
2M ago
ALGS
Aligos Therapeutics Reports Q3 2025 Progress and Financials
PremiumCompany Announcements
Aligos Therapeutics Reports Q3 2025 Progress and Financials
2M ago
ALGS
Aligos Therapeutics reports Q3 EPS ($3.04), consensus ($2.01)
PremiumThe Fly
Aligos Therapeutics reports Q3 EPS ($3.04), consensus ($2.01)
2M ago
ALGS
Aligos Therapeutics’ Promising Hepatitis B Study: A Potential Game-Changer?
PremiumCompany Announcements
Aligos Therapeutics’ Promising Hepatitis B Study: A Potential Game-Changer?
3M ago
ALGS
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
PremiumThe FlyAligos Therapeutics announces inducement grants under Nasdaq listing rule
3M ago
ALGS
Aligos Therapeutics receives USAN council approval for pevifoscorvir sodium
Premium
The Fly
Aligos Therapeutics receives USAN council approval for pevifoscorvir sodium
3M ago
ALGS
Positive Outlook on Aligos Therapeutics’ MASH Treatment Potential and Strategic Valuation
Premium
Ratings
Positive Outlook on Aligos Therapeutics’ MASH Treatment Potential and Strategic Valuation
3M ago
ALGS
Aligos Therapeutics’ Promising Drug Pipeline and Strategic Advancements Justify Buy Rating and $50 Price Target
PremiumRatings
Aligos Therapeutics’ Promising Drug Pipeline and Strategic Advancements Justify Buy Rating and $50 Price Target
4M ago
ALGS
Aligos Therapeutics appoints Ramon Polo as head of global regulatory affairs
PremiumThe Fly
Aligos Therapeutics appoints Ramon Polo as head of global regulatory affairs
5M ago
ALGS
Aligos Therapeutics: Promising Advancements in HBV Treatment and Strategic Pipeline Growth
PremiumRatings
Aligos Therapeutics: Promising Advancements in HBV Treatment and Strategic Pipeline Growth
5M ago
ALGS
Aligos Therapeutics assumed with a Buy at H.C. Wainwright
PremiumThe Fly
Aligos Therapeutics assumed with a Buy at H.C. Wainwright
5M ago
ALGS
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
PremiumThe FlyAligos Therapeutics announces inducement grants under Nasdaq listing rule
5M ago
ALGS
Aligos Therapeutics announces first subject dosed in Phase 2 B-SUPREME study
Premium
The Fly
Aligos Therapeutics announces first subject dosed in Phase 2 B-SUPREME study
5M ago
ALGS
Aligos Therapeutics Reports Q2 2025 Progress and Results
Premium
Company Announcements
Aligos Therapeutics Reports Q2 2025 Progress and Results
5M ago
ALGS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >